Ex­clu­sive: Af­ter get­ting his drug back, Lan­dos founder as­sem­bles new start­up for the big PhI­II test

By the time Josep Bas­saganya-Ri­era stepped down as found­ing CEO of Lan­dos Bio­phar­ma in 2021, the com­pa­ny had racked up Phase II da­ta for its top au­toim­mune pro­gram, com­plet­ed what he called a pos­i­tive end-of-Phase-II meet­ing with the FDA and plans to launch piv­otal Phase III tri­als.

Since then, though, the new lead­ers at Lan­dos have reshuf­fled their plans for the drug, omi­lan­cor, first an­nounc­ing they will run a Phase IIb ahead of a Phase III and even­tu­al­ly shelv­ing it al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER